Cite

HARVARD Citation

    Wang, Y. et al. (2021). Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncoimmunology. p. . [Online]. 
  
Back to record